WEBVTT

1
00:00:00.400 --> 00:00:03.120
<v Speaker 1>Welcome to our podcast on the Director's Notes in under

2
00:00:03.160 --> 00:00:06.839
<v Speaker 1>ten minutes for the fifteenth annual POD Partnership Opportunities and

3
00:00:06.919 --> 00:00:10.919
<v Speaker 1>Drug Delivery Conference, which takes place October twenty seventh and

4
00:00:10.960 --> 00:00:15.119
<v Speaker 1>twenty eighth in Boston. Valerie Boling, I'm the executive director

5
00:00:15.160 --> 00:00:17.440
<v Speaker 1>of the conference Forum, and I am delighted to be

6
00:00:17.519 --> 00:00:20.800
<v Speaker 1>joined by my colleague Andrew Goldstein, who is the senior

7
00:00:21.079 --> 00:00:22.879
<v Speaker 1>producer for the POD conference.

8
00:00:23.039 --> 00:00:26.239
<v Speaker 2>And Hello Andrew, and welcome, Hi, Valerie. Happy to be here.

9
00:00:26.359 --> 00:00:29.280
<v Speaker 1>Andrew. We're going to give highlights on what to expect

10
00:00:29.719 --> 00:00:33.799
<v Speaker 1>for the twenty twenty five conference. It is our fifteenth annual.

11
00:00:33.880 --> 00:00:37.240
<v Speaker 1>It's a celebration year, and we've seen so much over

12
00:00:37.280 --> 00:00:40.679
<v Speaker 1>those years. My goodness, and as always, we're so honored

13
00:00:40.719 --> 00:00:44.719
<v Speaker 1>to present this program with MIT's doctor Robert Langer, who

14
00:00:44.759 --> 00:00:49.399
<v Speaker 1>always gives an excellent keynote, and there's nobody like doctor Langer,

15
00:00:49.479 --> 00:00:51.679
<v Speaker 1>and it's always such a pleasure to have him, Andrew.

16
00:00:51.719 --> 00:00:55.359
<v Speaker 1>As you know, POD is a strategic level program. We

17
00:00:55.439 --> 00:00:58.039
<v Speaker 1>don't consider it a trade show. Although we have a

18
00:00:58.119 --> 00:01:02.079
<v Speaker 1>really interesting wide array of drug delivery companies for folks

19
00:01:02.079 --> 00:01:06.079
<v Speaker 1>to meet. There's so much partnering. It is a Partnering program,

20
00:01:06.439 --> 00:01:08.439
<v Speaker 1>and we do a lot of work to balance the

21
00:01:08.599 --> 00:01:12.319
<v Speaker 1>strategic level, high level content that we don't think you

22
00:01:12.480 --> 00:01:16.959
<v Speaker 1>really can get anywhere else because we have the advantage

23
00:01:17.000 --> 00:01:19.480
<v Speaker 1>of being an industry research firm where we can draw

24
00:01:19.560 --> 00:01:22.159
<v Speaker 1>on five areas of research that we cover here at

25
00:01:22.159 --> 00:01:25.200
<v Speaker 1>the conference form we can bring that to the POD program.

26
00:01:25.280 --> 00:01:28.680
<v Speaker 1>So that's part of its uniqueness. But we do have

27
00:01:28.799 --> 00:01:31.680
<v Speaker 1>about a thousand people now. So with that, Andrew, you

28
00:01:31.799 --> 00:01:34.680
<v Speaker 1>have been interviewing and researching with many, many pharma and

29
00:01:34.760 --> 00:01:38.519
<v Speaker 1>drug delivery companies. So based on your research, tell us

30
00:01:38.519 --> 00:01:39.519
<v Speaker 1>what the hot themes are.

31
00:01:39.799 --> 00:01:42.799
<v Speaker 2>Definitely, thank you, Valerie. So the POD conference has a

32
00:01:42.920 --> 00:01:47.319
<v Speaker 2>huge history reporting on cutting edge scientific trends and pharma

33
00:01:47.439 --> 00:01:51.680
<v Speaker 2>needs and drug delivery business deals and really everything in

34
00:01:51.719 --> 00:01:55.079
<v Speaker 2>the drug delivery space. This year, specifically, there's been an

35
00:01:55.120 --> 00:01:57.480
<v Speaker 2>increased focus on deal making and partnerships. I know that

36
00:01:57.560 --> 00:02:01.000
<v Speaker 2>might seem obvious for POD Partnership Conference, but there has

37
00:02:01.040 --> 00:02:03.719
<v Speaker 2>been an uptick in deals and so hearing on what

38
00:02:04.599 --> 00:02:07.840
<v Speaker 2>companies are interested in, how these deals work, what goes

39
00:02:07.840 --> 00:02:10.080
<v Speaker 2>into it from a scientific level, from a business level,

40
00:02:10.080 --> 00:02:13.039
<v Speaker 2>what the process looks like in terms of the scientific topics.

41
00:02:13.479 --> 00:02:18.159
<v Speaker 2>Lots of interest in delivering different therapeutics using different modalities,

42
00:02:18.840 --> 00:02:22.919
<v Speaker 2>selling gene and biologics delivery. The GLP one and other

43
00:02:22.960 --> 00:02:25.919
<v Speaker 2>incretin drugs have been coming up quite a lot, and

44
00:02:26.080 --> 00:02:31.919
<v Speaker 2>increased focus in combination device development, manufacturing and sustainability and

45
00:02:32.240 --> 00:02:37.240
<v Speaker 2>delivering high volume, high concentration therapeutics, as well as integrating

46
00:02:37.280 --> 00:02:39.800
<v Speaker 2>digital health and connected devices Andrew.

47
00:02:39.879 --> 00:02:43.240
<v Speaker 1>As you know, the POD conference has these classic sections

48
00:02:43.639 --> 00:02:47.439
<v Speaker 1>that people really love. For example, like an entire afternoon

49
00:02:47.479 --> 00:02:51.159
<v Speaker 1>on just the drug delivery presentations across modalities. So can

50
00:02:51.159 --> 00:02:53.879
<v Speaker 1>you give us a quick rundown on how it is

51
00:02:54.000 --> 00:02:57.479
<v Speaker 1>organized and you can go through the sections that people

52
00:02:57.560 --> 00:02:58.240
<v Speaker 1>can expect.

53
00:02:58.639 --> 00:03:01.560
<v Speaker 2>Definitely on the first and second days of the program,

54
00:03:01.680 --> 00:03:05.759
<v Speaker 2>we do have industry overviews from Roche and then from

55
00:03:05.759 --> 00:03:09.280
<v Speaker 2>Pharma Circle, just a year interview. What are the hot topics,

56
00:03:09.280 --> 00:03:11.080
<v Speaker 2>what are the deals being made, what are the trends

57
00:03:11.080 --> 00:03:14.360
<v Speaker 2>we're seeing in drug delivery. We also, this year, as

58
00:03:14.360 --> 00:03:17.759
<v Speaker 2>we have every year, the annual Company Spotlights, where pharma

59
00:03:17.840 --> 00:03:20.719
<v Speaker 2>companies will present on the technologies that they're interested in

60
00:03:20.759 --> 00:03:25.240
<v Speaker 2>and their partnership philosophies. This year, Nevardis and AVY are

61
00:03:25.280 --> 00:03:27.840
<v Speaker 2>signed on to speak about what they're looking for and

62
00:03:27.840 --> 00:03:30.520
<v Speaker 2>what they're interested in. And in addition to that, we

63
00:03:30.560 --> 00:03:33.800
<v Speaker 2>do have a panel on partnering and what that looks like,

64
00:03:33.919 --> 00:03:37.479
<v Speaker 2>how to do, what that process is, as well as

65
00:03:37.479 --> 00:03:40.800
<v Speaker 2>a fireside conversation about that as well. On the first

66
00:03:40.840 --> 00:03:43.080
<v Speaker 2>day of the program in the afternoon. We often call

67
00:03:43.159 --> 00:03:45.840
<v Speaker 2>this the crown jewel of the POD conference, we have

68
00:03:45.919 --> 00:03:50.479
<v Speaker 2>the drug delivery technology presentations. This year we have tracks

69
00:03:50.520 --> 00:03:55.479
<v Speaker 2>on injectible formulations and technologies, oral mucosal transderble and other

70
00:03:55.560 --> 00:04:00.439
<v Speaker 2>non injectible technologies, novel devices, self injectibles, where robles and

71
00:04:00.479 --> 00:04:06.840
<v Speaker 2>connective devices, selling gene delivery, excipient innovation, novel device technologies,

72
00:04:07.199 --> 00:04:12.360
<v Speaker 2>novel injectable and non injectible technologies, sell gene and novel biologics,

73
00:04:12.360 --> 00:04:17.720
<v Speaker 2>delivery and self injection devices, syringes, primary containers, and packaging solutions,

74
00:04:17.920 --> 00:04:22.680
<v Speaker 2>and so within these tracks, companies will present on new data,

75
00:04:22.800 --> 00:04:26.279
<v Speaker 2>what they're working on, their technologies, mechanisms of action, and

76
00:04:27.120 --> 00:04:29.519
<v Speaker 2>what they're looking for in terms of partnerships with pharma.

77
00:04:29.600 --> 00:04:32.800
<v Speaker 2>And within this area, I think we dedicate generally twenty

78
00:04:32.800 --> 00:04:36.560
<v Speaker 2>percent of the time specifically for emerging companies, so we

79
00:04:36.639 --> 00:04:41.079
<v Speaker 2>are getting both regulars and also new companies coming back

80
00:04:41.160 --> 00:04:41.680
<v Speaker 2>every year.

81
00:04:42.199 --> 00:04:42.480
<v Speaker 1>Nice.

82
00:04:42.519 --> 00:04:44.759
<v Speaker 2>In addition to that, on the second day of the program,

83
00:04:44.839 --> 00:04:49.600
<v Speaker 2>we have our annual pod Soapbox, where really young innovative

84
00:04:49.680 --> 00:04:53.560
<v Speaker 2>drug delivery companies give very quick presentations on what they're

85
00:04:53.600 --> 00:04:56.439
<v Speaker 2>working on, and then usually when they finish, we have

86
00:04:56.519 --> 00:04:58.560
<v Speaker 2>lunch and people could come over and speak to those

87
00:04:58.560 --> 00:04:59.879
<v Speaker 2>companies as well.

88
00:05:00.319 --> 00:05:04.560
<v Speaker 1>Nice. Nice. So we've got keynotes, panel discussions, We've got

89
00:05:04.720 --> 00:05:10.040
<v Speaker 1>our company spotlights talking about their partnering philosophies and what

90
00:05:10.079 --> 00:05:13.279
<v Speaker 1>they look for in drug delivery. We've got the afternoon

91
00:05:13.360 --> 00:05:17.199
<v Speaker 1>tracks as you just described, and we have other breakout choices.

92
00:05:17.240 --> 00:05:20.000
<v Speaker 1>We have the Soapbox. Anyhow, there are other highlights I know,

93
00:05:20.199 --> 00:05:22.680
<v Speaker 1>so tell us more about those definitely.

94
00:05:22.720 --> 00:05:25.120
<v Speaker 2>So I'd love to talk about the keynotes this year,

95
00:05:25.160 --> 00:05:27.759
<v Speaker 2>as every year, we have doctor Robert Langer from MIT,

96
00:05:28.319 --> 00:05:30.600
<v Speaker 2>and he's going to be speaking about the state of

97
00:05:30.600 --> 00:05:35.040
<v Speaker 2>innovation in drug delivery industry. This year, we're proud to

98
00:05:35.120 --> 00:05:40.879
<v Speaker 2>welcome doctor Latabierre Nudsen, Novo Nordisk's chief scientific advisor, who

99
00:05:41.000 --> 00:05:45.319
<v Speaker 2>drove the development of GLP drugs for obesity, and she's

100
00:05:45.319 --> 00:05:47.959
<v Speaker 2>going to present on the lyric glue tide and sema

101
00:05:48.000 --> 00:05:51.360
<v Speaker 2>glue tide story. Her approach to scientific development and where

102
00:05:51.399 --> 00:05:53.199
<v Speaker 2>drug delivery intersects with her R.

103
00:05:53.160 --> 00:05:53.720
<v Speaker 1>And D work.

104
00:05:54.240 --> 00:05:57.800
<v Speaker 2>We also have a patient keynote this year, Jamie Oligiri,

105
00:05:58.279 --> 00:06:01.160
<v Speaker 2>who will share his he as a patient with sickle

106
00:06:01.240 --> 00:06:04.800
<v Speaker 2>cell disease before and after receiving CASKEV, which is a

107
00:06:04.920 --> 00:06:08.879
<v Speaker 2>crisper based therapy for sickle cell disease, and his mission

108
00:06:08.920 --> 00:06:12.839
<v Speaker 2>to make these therapies more accessible for patients globally. Additionally,

109
00:06:12.879 --> 00:06:16.680
<v Speaker 2>we have a Zeitgeist presenter in doctor Mensor Emigi, who

110
00:06:16.759 --> 00:06:20.480
<v Speaker 2>is a University Distinguished Professor at Northeastern University. He's going

111
00:06:20.519 --> 00:06:24.759
<v Speaker 2>to speak on endogenoust targeted delivery, different strategies to overcome

112
00:06:24.800 --> 00:06:27.639
<v Speaker 2>biological barriers and improve efficacy and safety.

113
00:06:28.040 --> 00:06:30.839
<v Speaker 1>And to add to this wonderful list of keynotes, I

114
00:06:30.879 --> 00:06:33.879
<v Speaker 1>am absolutely delighted that we have for the first time

115
00:06:33.920 --> 00:06:37.240
<v Speaker 1>at POD doctor George Young Coppolis, who of course is

116
00:06:37.279 --> 00:06:40.720
<v Speaker 1>the co founder of Regeneron, and not only is he

117
00:06:40.800 --> 00:06:44.279
<v Speaker 1>a great innovative thinker and doer, but he's just an

118
00:06:44.279 --> 00:06:48.839
<v Speaker 1>excellent leader in this space. So just really delighted that

119
00:06:49.600 --> 00:06:52.439
<v Speaker 1>doctor Young Coppolis will be joining doctor Robert Langer on

120
00:06:52.480 --> 00:06:53.199
<v Speaker 1>the stage.

121
00:06:53.639 --> 00:06:56.360
<v Speaker 2>Also returning this year to the POD conference. I think

122
00:06:56.399 --> 00:07:00.519
<v Speaker 2>it's the fourth time we have a panel from haayers

123
00:07:01.040 --> 00:07:04.240
<v Speaker 2>sharing their perspectives on drug delivery. This year, they're going

124
00:07:04.279 --> 00:07:08.920
<v Speaker 2>to cover the pharmacoeconomics of drug delivery, enable drug products

125
00:07:08.959 --> 00:07:12.199
<v Speaker 2>demonstrating value to the patient and system versus just a

126
00:07:12.240 --> 00:07:16.120
<v Speaker 2>pricing comparison to products already on the market, Pressures on

127
00:07:16.199 --> 00:07:19.639
<v Speaker 2>drug pricing and leveraging health economics, as well as trends

128
00:07:19.639 --> 00:07:23.399
<v Speaker 2>in coverage and pricing for incretins and nucleic acid drugs.

129
00:07:23.879 --> 00:07:27.720
<v Speaker 1>Wow, Okay, that's a lot, Andrew fantastic. So are there

130
00:07:27.720 --> 00:07:30.759
<v Speaker 1>any other highlights you want to bring forward to us?

131
00:07:30.800 --> 00:07:33.360
<v Speaker 2>Definitely. So on the second day of the program, after lunch,

132
00:07:33.600 --> 00:07:36.360
<v Speaker 2>we're going to have our panel tracks, and so this

133
00:07:36.480 --> 00:07:39.240
<v Speaker 2>year we've split it up into four tracks. The first

134
00:07:39.279 --> 00:07:43.600
<v Speaker 2>track is Novel Formulations, where we'll speak about novel vehicles

135
00:07:43.639 --> 00:07:47.959
<v Speaker 2>to deliver genetic medicines, tissue specific targeting for nucleic acid

136
00:07:48.040 --> 00:07:52.519
<v Speaker 2>therapies ADCs, and other approaches for drug conjugation and bioconjugation,

137
00:07:53.199 --> 00:07:56.920
<v Speaker 2>oral delivery of biologics and peptides, and sustained release and

138
00:07:56.959 --> 00:08:00.000
<v Speaker 2>long acting delivery. Then we'll have a track on novel

139
00:08:00.120 --> 00:08:04.879
<v Speaker 2>delivery modalities where we'll talk about brain delivery, transdermal delivery, vaccines,

140
00:08:05.160 --> 00:08:09.639
<v Speaker 2>ophthalmic delivery, and then respiratory devices and inhale biologics. We

141
00:08:09.680 --> 00:08:12.879
<v Speaker 2>will have a combination device track that will speak on

142
00:08:13.120 --> 00:08:19.000
<v Speaker 2>platform approaches to develop combination product developing, a global regulatory framework,

143
00:08:19.399 --> 00:08:24.399
<v Speaker 2>preparing for manufacturing, scale up for commercialization or clinic sustainability

144
00:08:24.480 --> 00:08:29.560
<v Speaker 2>throughout the process, and then using AI in combination product development.

145
00:08:29.879 --> 00:08:33.679
<v Speaker 2>And lastly, a novel Drug delivery and Device technologies track

146
00:08:33.960 --> 00:08:37.440
<v Speaker 2>where we'll discuss transitioning from IV to SubQ and how

147
00:08:37.440 --> 00:08:42.399
<v Speaker 2>that impacts workflow and patients, Dual chamber injectibles and advances

148
00:08:42.440 --> 00:08:46.759
<v Speaker 2>in that area, Digital tech for improving patient experience and

149
00:08:47.039 --> 00:08:51.120
<v Speaker 2>preparing the supply chain delivering hyper concentrated formulations, and then

150
00:08:51.159 --> 00:08:54.480
<v Speaker 2>also large volume delivery. Nice Valarie, if I can ask

151
00:08:54.519 --> 00:08:57.399
<v Speaker 2>you a question, I'd love to get your thoughts on

152
00:08:57.559 --> 00:08:59.840
<v Speaker 2>the networking opportunities at the conference.

153
00:09:00.080 --> 00:09:03.919
<v Speaker 1>Yeah. No, it's really important that we have very intentionally

154
00:09:04.039 --> 00:09:08.639
<v Speaker 1>prepared tools and support for people to partner because that's

155
00:09:08.720 --> 00:09:12.200
<v Speaker 1>what it's all about, right. So we've got companies who

156
00:09:12.279 --> 00:09:18.440
<v Speaker 1>have an array of different drug delivery solutions or possibilities,

157
00:09:18.919 --> 00:09:21.600
<v Speaker 1>and we have an array of pharm and biotech companies

158
00:09:21.600 --> 00:09:26.480
<v Speaker 1>who are looking for those solutions. So it's really important.

159
00:09:26.519 --> 00:09:30.080
<v Speaker 1>And I've always noticed that with the POD conference that

160
00:09:30.519 --> 00:09:34.480
<v Speaker 1>people come very organized, they're very intentional. They're there to

161
00:09:34.759 --> 00:09:38.440
<v Speaker 1>really meet people and talk about the science and the

162
00:09:39.200 --> 00:09:42.879
<v Speaker 1>challenges that they're having. So you see that it's always

163
00:09:43.559 --> 00:09:47.279
<v Speaker 1>just packed. The partnering like all of the partnering tables,

164
00:09:47.399 --> 00:09:50.120
<v Speaker 1>and we make sure that we have our folks on

165
00:09:50.159 --> 00:09:53.039
<v Speaker 1>the ground to make sure that there's never not a

166
00:09:53.080 --> 00:09:56.120
<v Speaker 1>table available for people. We take the partnering very seriously

167
00:09:56.639 --> 00:10:00.879
<v Speaker 1>and we have different sections where people can partner. We're

168
00:10:00.879 --> 00:10:02.519
<v Speaker 1>going to have a new partnering tool, which I'm very

169
00:10:02.519 --> 00:10:06.279
<v Speaker 1>excited about. If somebody can't reach somebody, we have staff

170
00:10:06.360 --> 00:10:10.080
<v Speaker 1>on site, a dedicated partnering desk to help people bind

171
00:10:10.120 --> 00:10:14.120
<v Speaker 1>the people that they're looking for. So partnering is huge. Again,

172
00:10:14.200 --> 00:10:17.360
<v Speaker 1>the tool, the tables, and the on site support have

173
00:10:17.879 --> 00:10:20.440
<v Speaker 1>the morning breaks, the afternoon breaks, and we also have

174
00:10:20.519 --> 00:10:24.039
<v Speaker 1>an annual reception for people to network and for people

175
00:10:24.039 --> 00:10:27.200
<v Speaker 1>to meet those exhibitors, and of course a lot of

176
00:10:27.200 --> 00:10:29.799
<v Speaker 1>partnering does happen at the exhibit tables. You know, our

177
00:10:29.840 --> 00:10:34.399
<v Speaker 1>exhibitors are always so incredibly organized and the room is

178
00:10:34.399 --> 00:10:37.480
<v Speaker 1>always just so full, and so, you know, so you

179
00:10:37.519 --> 00:10:39.559
<v Speaker 1>see the partnering at the tables, but you also see

180
00:10:39.559 --> 00:10:42.120
<v Speaker 1>it at the exhibit tables as well. So I hope

181
00:10:42.120 --> 00:10:43.879
<v Speaker 1>that you know, it gives everyone a sense of the

182
00:10:43.960 --> 00:10:46.159
<v Speaker 1>kind of networking that we have. It's very intentional, it's

183
00:10:46.200 --> 00:10:49.120
<v Speaker 1>well organized, but we also balance it with just hey,

184
00:10:49.159 --> 00:10:51.159
<v Speaker 1>I just want to get a drink at the reception

185
00:10:51.240 --> 00:10:53.480
<v Speaker 1>and just talk to people without having to have a

186
00:10:53.519 --> 00:10:57.039
<v Speaker 1>partnering planned meeting. That's okay too. So with that, where

187
00:10:57.039 --> 00:10:58.519
<v Speaker 1>can people go to get more information?

188
00:10:59.000 --> 00:11:02.799
<v Speaker 2>Thank you Alleri. So people can go to podconference dot

189
00:11:02.840 --> 00:11:05.840
<v Speaker 2>com that's Pod with two d's to learn more about

190
00:11:05.879 --> 00:11:08.960
<v Speaker 2>the conference. You can see the agenda, the speaking faculty,

191
00:11:09.120 --> 00:11:12.440
<v Speaker 2>the exhibiting companies and other sponsoring companies and learn more

192
00:11:12.440 --> 00:11:14.759
<v Speaker 2>about the conference. And in addition to that, we cover

193
00:11:14.919 --> 00:11:18.679
<v Speaker 2>the drug delivery market throughout the year through editorials, podcasts,

194
00:11:18.720 --> 00:11:21.960
<v Speaker 2>and webcasts and you can see all of that at

195
00:11:22.080 --> 00:11:23.679
<v Speaker 2>drug Dashdelivery dot org.

196
00:11:24.320 --> 00:11:26.919
<v Speaker 1>All right, excellent, Andrew, thank you so much, and thanks everyone.

197
00:11:27.399 --> 00:11:28.120
<v Speaker 2>Thank you. Valerie